- New Algorithm for Estimating Left Ventricular Filling Pressure by Echocardiography
- Mitochondrial 1-Carbon Metabolism Drives CD34-Lineage Cells to Differentiate Into T Follicular Helper Cells to Form Tertiary Lymphoid Organs in Transplant Arteriosclerosis
- Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial
- Response by Duan and Lin to Letter Regarding Article, “Bone Morphogenetic Protein 9 Protects Against Myocardial Infarction by Improving Lymphatic Drainage Function and Triggering DECR1-Mediated Mitochondrial Bioenergetics”
- Correction to: Toward Heart-Healthy and Sustainable Cities: A Policy Statement From the American Heart Association
- Confounders, Effect Modifiers, and Mediators: Dealing With “Third Variables” in Cardiovascular Epidemiology
- Letter by Wang et al Regarding Article, “Bone Morphogenetic Protein 9 Protects Against Myocardial Infarction by Improving Lymphatic Drainage Function and Triggering DECR1-Mediated Mitochondrial Bioenergetics”
- Nonculprit Vulnerable Plaques and Prognosis in Myocardial Infarction With Versus Without ST-Segment Elevation: A PROSPECT II Substudy
- Insights Into Recovery From Acute Fulminant Myocarditis Following Successful Treatment With Ruxolitinib by Comprehensive Single-Cell Profiling
- Correction to: 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
- Correction to: 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
- Correction to: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
- A Systematic Review of “Food Is Medicine” Randomized Controlled Trials for Noncommunicable Disease in the United States: A Scientific Statement From the American Heart Association
- Family Screening in Relatives at Risk for Plakophilin-2–Associated Arrhythmogenic Right Ventricular Cardiomyopathy
- Inactivation of RhoA for Hypertension Treatment Through the TRPV4–RhoA–RhoGDI1 Axis
Esprimi il gradimento a questo contenuto
[Totale voti: 0 Media: 0]
